From bioworld.com
Elixir’s Dynamx bioadaptor meets primary endpoint
2 2
Elixir Medical Corp. reported positive 12-month data from the Infinity-Swedeheart trial that compared its Dynamx coronary bioadaptor system to Medtronic plc’s Resolute Onyx zotarolimus drug-eluting stent in patients requiring percutaneous coronary intervention with coronary artery disease.
#doctor #medtech #hospital #medicine #medgadget #bioadaptor #healthcare #healthtech #healthcaretech #healthtechnology
on Sep 6